| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6189900 | Bulletin du Cancer | 2016 | 8 Pages |
Abstract
The introduction of lenalidomide into the therapeutic arsenal of hematologic malignancies has represented an important step forward in the management of multiple myeloma. However, its use is associated with several toxicities including kidney injury. The present review examines the drug's pharmacokinetics, discusses the main adverse renal effects that are associated with lenalidomide treatment, and makes recommendations for dosage adjustment in patients with underlying renal impairment.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Rania Kheder El-Fekih, Hassan Izzedine,